Clinical Trials Recruiting near Chicago, IL

2,144 clinical trials have a recruiting site within 25 miles of Chicago, Illinois, according to ClinicalTrials.gov data processed October 15, 2026. The closest recruiting site is within 1 mile of the city center.

Distances are measured from the city center to each site's city, so they are approximate.

Recruiting now

Studies enrolling near Chicago

Showing 30 studies, nearest first.

MILD® Percutaneous Image-Guided Lumbar Decompression: A Medicare Claims Study
NCT03072927
- Observational
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
51 sites within 25 mi
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926
- Phase 3
- Ages 18 to 60 years
- Sex: Female
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
30 sites within 25 mi
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT05929768
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
29 sites within 25 mi
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
NCT03851445
- Phase 2/3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
28 sites within 25 mi
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
NCT05174169
- Phase 2/3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
26 sites within 25 mi
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT05812807
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
22 sites within 25 mi
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
NCT06876714
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
22 sites within 25 mi
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
NCT05564390
- Phase 2
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
19 sites within 25 mi
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab
NCT05675410
- Phase 3
- Ages 5 to 60 years
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
19 sites within 25 mi
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
NCT04852887
- Phase 3
- Ages 50 to 70 years
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
18 sites within 25 mi
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
NCT05564377
- Phase 2
- Ages Any age
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
18 sites within 25 mi
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
NCT05987241
- Phase 2/3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
17 sites within 25 mi
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
NCT04267848
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
16 sites within 25 mi
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
NCT06203600
- Phase 2/3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
16 sites within 25 mi
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
NCT04251052
- Interventional
- Ages 35 to 50 years
- Sex: Female
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
15 sites within 25 mi
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
NCT06116682
- Phase 2
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
15 sites within 25 mi
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NCT06580314
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
15 sites within 25 mi
Improving Safety, Patient Experience and Equity Through Shared Decision-making Huddles in Labor
NCT06828406
- Interventional
- Ages 18 years and older
- Sex: Female
- Accepts healthy volunteers
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
15 sites within 25 mi
Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer
NCT06058377
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
14 sites within 25 mi
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
NCT06616584
- Phase 2/3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
14 sites within 25 mi
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
NCT06661720
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
14 sites within 25 mi
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
NCT04510597
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
13 sites within 25 mi
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
NCT05642572
- Phase 2
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
13 sites within 25 mi
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
NCT05677490
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
13 sites within 25 mi
Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid Cancer
NCT06475989
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
13 sites within 25 mi
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated Sarcomas
NCT06422806
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
12 sites within 25 mi
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
NCT06958328
- Phase 3
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
12 sites within 25 mi
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
NCT02523014
- Phase 2
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
11 sites within 25 mi
Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
NCT04242095
- Observational
- Ages Any age
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
11 sites within 25 mi
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
NCT06317649
- Phase 2
- Ages 18 years and older
- Sex: All
Distance to nearest recruiting site
<1 mi (city-level)
Recruiting sites
11 sites within 25 mi

Source: ClinicalTrials.gov, data processed October 15, 2026. Recruiting US sites filtered by distance and site status; summaries shortened.